• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Toll样受体2(TLR2)抑制可改善脂多糖(LPS)对肝细胞脂质蓄积和脂毒性的放大作用。

TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells.

作者信息

Zhang Liting, Xie Zehui, Yu Hongmiao, Du Haoxuan, Wang Xuqiao, Cai Jiazheng, Qiu Yingfei, Chen Rui, Jiang Xiaofeng, Liu Zelin, Li Yi, Chen Tuo

机构信息

State Key Laboratory of Cryospheric Science, Northwest Institute of Eco-Environment and Resources, Chinese Academy of Sciences, Lanzhou, China.

University of Chinese Academy of Sciences, Beijing, China.

出版信息

Ann Transl Med. 2021 Sep;9(18):1429. doi: 10.21037/atm-21-4012.

DOI:10.21037/atm-21-4012
PMID:34733981
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8506759/
Abstract

BACKGROUND

Gut microbiome dysbiosis is related to the pathogenesis of nonalcoholic fatty liver disease (NAFLD), and the role of toll-like receptor 2 (TLR2) in its molecular mechanism is controversial. Here, we investigated the effects and mechanisms of -derived lipopolysaccharide (LPS) on lipid accumulation and lipotoxicity in palmitic acid (PA)-treated L02 cell as an NAFLD cell model, and the role of TLR2 in this process.

METHODS

Oil red O staining assay and free fatty acid (FFA) content test were performed to determine the effects of LPS on lipid accumulation in a PA-induced NAFLD cell model with or without TLR2 inhibition. The levels of IL-6 and TNF-α were measured to investigate inflammation conditions. Hoechst 33342 staining assay and Caspase-3 activity assay were used to test cell apoptosis, and the expression levels of proteins in the IRS1/PI3K/AKT signaling pathway, TLR2/MyD88/IKKα/NF-κB signaling pathway, and mitochondrion-dependent apoptotic signaling pathway were detected using Western blot.

RESULTS

Lipid accumulation, pro-inflammatory cytokine release, and cell apoptosis with high levels were observed in the PA-induced NAFLD cell model, and LPS aggravated these processes. Whereas TLR2 inhibition could significantly ameliorate PA-induced and LPS-amplified lipid accumulation, inflammatory, and cell apoptosis, it had no significant effect on L02 cells treated with LPS alone.

CONCLUSIONS

These results were confirmed by activation or inhibition of the IRS1/PI3K/AKT signaling pathway, TLR2/MyD88/IKKα/NF-κB signaling pathway, and mitochondrion-dependent apoptotic signaling pathway, and were reflected by changes on their proteins expression. TLR2 is involved in PA-induced lipid accumulation and lipotoxicity in L02 cells, which could be aggravated by LPS, although LPS-induced amplification might not be through direct interaction with TLR2.

摘要

背景

肠道微生物群失调与非酒精性脂肪性肝病(NAFLD)的发病机制有关,而Toll样受体2(TLR2)在其分子机制中的作用存在争议。在此,我们研究了细菌衍生的脂多糖(LPS)对棕榈酸(PA)处理的L02细胞(作为NAFLD细胞模型)中脂质积累和脂毒性的影响及机制,以及TLR2在此过程中的作用。

方法

进行油红O染色试验和游离脂肪酸(FFA)含量检测,以确定LPS对有或无TLR2抑制的PA诱导的NAFLD细胞模型中脂质积累的影响。检测白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平以研究炎症情况。采用Hoechst 33342染色试验和半胱天冬酶-3(Caspase-3)活性检测来检测细胞凋亡,并使用蛋白质印迹法检测胰岛素受体底物1(IRS1)/磷脂酰肌醇-3激酶(PI3K)/蛋白激酶B(AKT)信号通路、TLR2/髓样分化因子88(MyD88)/核因子κB抑制蛋白激酶α(IKKα)/核因子κB(NF-κB)信号通路以及线粒体依赖性凋亡信号通路中蛋白质的表达水平。

结果

在PA诱导的NAFLD细胞模型中观察到脂质积累、促炎细胞因子释放以及高水平的细胞凋亡,且LPS加剧了这些过程。而TLR2抑制可显著改善PA诱导的以及LPS增强的脂质积累、炎症反应和细胞凋亡,对单独用LPS处理的L02细胞无显著影响。

结论

这些结果通过激活或抑制IRS1/PI3K/AKT信号通路、TLR2/MyD88/IKKα/NF-κB信号通路以及线粒体依赖性凋亡信号通路得到证实,并通过其蛋白质表达的变化得以体现。TLR2参与了PA诱导的L02细胞脂质积累和脂毒性,LPS可使其加重,尽管LPS诱导的增强作用可能不是通过与TLR2直接相互作用实现的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec1/8506759/a3219bf0bfc4/atm-09-18-1429-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec1/8506759/61432542a779/atm-09-18-1429-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec1/8506759/f4b8f0985865/atm-09-18-1429-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec1/8506759/445f17b7db31/atm-09-18-1429-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec1/8506759/a3219bf0bfc4/atm-09-18-1429-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec1/8506759/61432542a779/atm-09-18-1429-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec1/8506759/f4b8f0985865/atm-09-18-1429-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec1/8506759/445f17b7db31/atm-09-18-1429-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aec1/8506759/a3219bf0bfc4/atm-09-18-1429-f4.jpg

相似文献

1
TLR2 inhibition ameliorates the amplification effect of LPS on lipid accumulation and lipotoxicity in hepatic cells.Toll样受体2(TLR2)抑制可改善脂多糖(LPS)对肝细胞脂质蓄积和脂毒性的放大作用。
Ann Transl Med. 2021 Sep;9(18):1429. doi: 10.21037/atm-21-4012.
2
PPAR δ inhibition protects against palmitic acid-LPS induced lipidosis and injury in cultured hepatocyte L02 cell.过氧化物酶体增殖物激活受体 δ 抑制可防止棕榈酸-脂多糖诱导的培养肝细胞 L02 细胞脂肪变性和损伤。
Int J Med Sci. 2019 Oct 21;16(12):1593-1603. doi: 10.7150/ijms.37677. eCollection 2019.
3
Gypenosides improves nonalcoholic fatty liver disease induced by high-fat diet induced through regulating LPS/TLR4 signaling pathway.绞股蓝总苷通过调节 LPS/TLR4 信号通路改善高脂饮食诱导的非酒精性脂肪肝病。
Cell Cycle. 2020 Nov;19(22):3042-3053. doi: 10.1080/15384101.2020.1829800. Epub 2020 Oct 29.
4
Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-κB and JNK signaling pathways.牙龈卟啉单胞菌来源的脂多糖通过激活 NF-κB 和 JNK 信号通路导致肝脏脂质过度积累。
Oral Dis. 2019 Oct;25(7):1789-1797. doi: 10.1111/odi.13153. Epub 2019 Jul 28.
5
Lipopolysaccharide Preparation Derived From Induces a Weaker Immuno-Inflammatory Response in BV-2 Microglial Cells Than by Differentially Activating TLR2/4-Mediated NF-κB/STAT3 Signaling Pathways.脂多糖制剂诱导 BV-2 小胶质细胞产生的免疫炎症反应弱于 ,这是通过差异化激活 TLR2/4 介导的 NF-κB/STAT3 信号通路实现的。
Front Cell Infect Microbiol. 2021 Mar 18;11:606986. doi: 10.3389/fcimb.2021.606986. eCollection 2021.
6
Prolyl Oligopeptidase Inhibition Attenuates Steatosis in the L02 Human Liver Cell Line.脯氨酰寡肽酶抑制可减轻L02人肝细胞系中的脂肪变性。
PLoS One. 2016 Oct 19;11(10):e0165224. doi: 10.1371/journal.pone.0165224. eCollection 2016.
7
Fetuin A promotes lipotoxicity in β cells through the TLR4 signaling pathway and the role of pioglitazone in anti-lipotoxicity.胎球蛋白A通过Toll样受体4信号通路促进β细胞的脂毒性以及吡格列酮在抗脂毒性中的作用。
Mol Cell Endocrinol. 2015 Sep 5;412:1-11. doi: 10.1016/j.mce.2015.05.014. Epub 2015 May 15.
8
Upstream stimulatory factor 2 (USF2) induced upregulation of triggering receptor expressed on myeloid cells 1 (TREM1) promotes endometritis by regulating toll-like receptor (TLR) 2/4-nuclear factor-kappaB (NF-κB) signaling pathway.上游刺激因子 2(USF2)诱导髓样细胞表达的触发受体 1(TREM1)的上调通过调节 toll 样受体(TLR)2/4-核因子-κB(NF-κB)信号通路促进子宫内膜炎。
Bioengineered. 2022 Feb;13(2):3609-3619. doi: 10.1080/21655979.2022.2030619.
9
LB100 ameliorates nonalcoholic fatty liver disease the AMPK/Sirt1 pathway.LB100 通过 AMPK/Sirt1 通路改善非酒精性脂肪性肝病。
World J Gastroenterol. 2019 Dec 7;25(45):6607-6618. doi: 10.3748/wjg.v25.i45.6607.
10
Glycyrrhizin inactivates toll-like receptor (TLR) signaling pathway to reduce lipopolysaccharide-induced acute lung injury by inhibiting TLR2.甘草酸通过抑制 TLR2 失活 Toll 样受体 (TLR) 信号通路,减轻脂多糖诱导的急性肺损伤。
J Cell Physiol. 2019 Apr;234(4):4597-4607. doi: 10.1002/jcp.27242. Epub 2018 Sep 10.

引用本文的文献

1
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.代谢功能障碍相关脂肪性肝病:分子机制、临床意义及新兴治疗策略
Int J Mol Sci. 2025 Mar 25;26(7):2959. doi: 10.3390/ijms26072959.
2
Reducing microglial lipid load enhances β amyloid phagocytosis in an Alzheimer's disease mouse model.在阿尔茨海默病小鼠模型中,降低小胶质细胞脂质负荷可增强β淀粉样蛋白的吞噬作用。
Sci Adv. 2025 Feb 7;11(6):eadq6038. doi: 10.1126/sciadv.adq6038. Epub 2025 Feb 5.
3
Rifaximin prophylaxis in MASLD‑hepatocellular carcinoma: Lessons from a negative animal model.

本文引用的文献

1
The Role of the Microbiome in Liver Cancer.微生物群在肝癌中的作用。
Cancers (Basel). 2021 May 12;13(10):2330. doi: 10.3390/cancers13102330.
2
Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions.代谢性内毒素血症在全身炎症中的作用及潜在干预措施
Front Immunol. 2021 Jan 11;11:594150. doi: 10.3389/fimmu.2020.594150. eCollection 2020.
3
Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.肠道菌群与脂肪性肝病:已知、未知与未来。
利福昔明预防非酒精性脂肪性肝炎相关肝细胞癌:来自阴性动物模型的经验教训。
Biomed Rep. 2024 Oct 24;22(1):4. doi: 10.3892/br.2024.1882. eCollection 2025 Jan.
4
Lipidomics Analysis of Human HMC3 Microglial Cells in an In Vitro Model of Metabolic Syndrome.代谢综合征体外模型中人源 HMC3 小胶质细胞的脂质组学分析。
Biomolecules. 2024 Sep 30;14(10):1238. doi: 10.3390/biom14101238.
5
Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway.复方化浊方通过调节自噬和脂质合成信号通路缓解高脂饮食诱导的非酒精性脂肪肝病。
World J Gastroenterol. 2024 Aug 14;30(30):3584-3608. doi: 10.3748/wjg.v30.i30.3584.
6
Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis.肝细胞 CYR61 将致纤维性巨噬细胞极化以协调 NASH 纤维化。
Sci Transl Med. 2023 Sep 27;15(715):eade3157. doi: 10.1126/scitranslmed.ade3157.
7
Type 2 Diabetes Mellitus and Liver Disease: Across the Gut-Liver Axis from Fibrosis to Cancer.2 型糖尿病与肝脏疾病:从肝纤维化到肝癌的肝肠轴途径。
Nutrients. 2023 May 29;15(11):2521. doi: 10.3390/nu15112521.
Cell Host Microbe. 2020 Aug 12;28(2):233-244. doi: 10.1016/j.chom.2020.07.007.
4
Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review.水飞蓟素作为肝脏疾病的辅助治疗:叙述性综述。
Adv Ther. 2020 Apr;37(4):1279-1301. doi: 10.1007/s12325-020-01251-y. Epub 2020 Feb 17.
5
PPAR δ inhibition protects against palmitic acid-LPS induced lipidosis and injury in cultured hepatocyte L02 cell.过氧化物酶体增殖物激活受体 δ 抑制可防止棕榈酸-脂多糖诱导的培养肝细胞 L02 细胞脂肪变性和损伤。
Int J Med Sci. 2019 Oct 21;16(12):1593-1603. doi: 10.7150/ijms.37677. eCollection 2019.
6
Nonalcoholic fatty liver disease with advanced fibrosis as a multi-systemic disease: proceed with caution.非酒精性脂肪性肝病伴晚期纤维化作为一种多系统疾病:需谨慎对待。
Hepatobiliary Surg Nutr. 2019 Apr;8(2):170-172. doi: 10.21037/hbsn.2018.12.08.
7
Altered Microbiome in Patients With Cirrhosis and Complications.肝硬化及并发症患者的肠道微生物组改变。
Clin Gastroenterol Hepatol. 2019 Jan;17(2):307-321. doi: 10.1016/j.cgh.2018.08.008. Epub 2018 Aug 9.
8
Lipotoxicity and the gut-liver axis in NASH pathogenesis.脂毒性与 NASH 发病机制中的肠-肝轴
J Hepatol. 2018 Feb;68(2):280-295. doi: 10.1016/j.jhep.2017.11.014. Epub 2017 Nov 14.
9
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.肠道微生物群与非酒精性脂肪性肝病:机制与治疗的新视角。
Nutrients. 2017 Oct 16;9(10):1124. doi: 10.3390/nu9101124.
10
New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD).深入探讨器官间串扰在非酒精性脂肪性肝病(NAFLD)发病机制中的作用。
Protein Cell. 2018 Feb;9(2):164-177. doi: 10.1007/s13238-017-0436-0. Epub 2017 Jun 22.